Functional proteomics outlines the complexity of breast cancer molecular subtypes

[1]  M. Zabel,et al.  Prolactin-induced protein as a potential therapy response marker of adjuvant chemotherapy in breast cancer patients. , 2016, American journal of cancer research.

[2]  P. Maín,et al.  Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications. , 2015, Cancer research.

[3]  P. Hall,et al.  Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer , 2015, Clinical Proteomics.

[4]  L. Pusztai,et al.  Multigene prognostic tests in breast cancer: past, present, future , 2015, Breast Cancer Research.

[5]  Christopher R. Myers,et al.  A robust and efficient method for estimating enzyme complex abundance and metabolic flux from expression data , 2014, Comput. Biol. Chem..

[6]  C. Denkert,et al.  Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes , 2014, BMC Cancer.

[7]  A. Naderi,et al.  Prolactin-induced protein is required for cell cycle progression in breast cancer. , 2014, Neoplasia.

[8]  Toshima Z. Parris,et al.  Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma , 2014, International journal of cancer.

[9]  J. M. Jerez,et al.  A microRNA Signature Associated with Early Recurrence in Breast Cancer , 2014, PloS one.

[10]  S. K. Baniwal,et al.  Prolactin-Induced Protein (PIP) Regulates Proliferation of Luminal A Type Breast Cancer Cells in an Estrogen-Independent Manner , 2013, PloS one.

[11]  C. Denkert,et al.  Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes , 2014, BMC Cancer.

[12]  Keerthana Krishnan,et al.  miR-139-5p is a regulator of metastatic pathways in breast cancer , 2013, RNA.

[13]  Jian Weng,et al.  Cavin-3 dictates the balance between ERK and Akt signaling , 2013, eLife.

[14]  G. Tse,et al.  Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. , 2013, Human pathology.

[15]  E. Espinosa,et al.  Shotgun proteomics of archival triple‐negative breast cancer samples , 2013, Proteomics. Clinical applications.

[16]  Ronan M. T. Fleming,et al.  A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.

[17]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Jin-hai Tang,et al.  miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer , 2013, Experimental and therapeutic medicine.

[19]  Raphaël Porcher,et al.  Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 , 2013, Breast Cancer Research.

[20]  G. Sauter,et al.  Clinical Relevance of Loss of 11p15 in Primary and Metastatic Breast Cancer: Association with Loss of PRKCDBP Expression in Brain Metastases , 2012, PloS one.

[21]  G. Mills,et al.  Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer , 2012, Breast Cancer Research.

[22]  A. Naderi,et al.  Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer , 2012, Breast Cancer Research.

[23]  Kikuya Kato,et al.  Strategy for SRM-based verification of biomarker candidates discovered by iTRAQ method in limited breast cancer tissue samples. , 2012, Journal of proteome research.

[24]  J. Mefford,et al.  Stromal Genes Add Prognostic Information to Proliferation and Histoclinical Markers: A Basis for the Next Generation of Breast Cancer Gene Signatures , 2012, PloS one.

[25]  Jürgen Cox,et al.  Super-SILAC Allows Classification of Diffuse Large B-cell Lymphoma Subtypes by Their Protein Expression Profiles* , 2012, Molecular & Cellular Proteomics.

[26]  Moyez Dharsee,et al.  Proteomic Analyses Reveal High Expression of Decorin and Endoplasmin (HSP90B1) Are Associated with Breast Cancer Metastasis and Decreased Survival , 2012, PloS one.

[27]  F. Bertucci,et al.  A refined molecular taxonomy of breast cancer , 2011, Oncogene.

[28]  Charles M. Perou,et al.  Practical implications of gene-expression-based assays for breast oncologists , 2012, Nature Reviews Clinical Oncology.

[29]  Jeffrey T. Chang,et al.  Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer , 2012, Breast Cancer Research.

[30]  Suzy V. Torti,et al.  An iron regulatory gene signature predicts outcome in breast cancer. , 2011, Cancer research.

[31]  Pablo C. Echeverría,et al.  An Interaction Network Predicted from Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone Machine , 2011, PloS one.

[32]  E. Espinosa,et al.  Protein phosphorylation analysis in archival clinical cancer samples by shotgun and targeted proteomics approaches. , 2011, Molecular bioSystems.

[33]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2011. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Mann,et al.  Andromeda: a peptide search engine integrated into the MaxQuant environment. , 2011, Journal of proteome research.

[35]  Ronan M. T. Fleming,et al.  Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.

[36]  C. Castañeda,et al.  The present and future of gene profiling in breast cancer , 2011, Cancer and Metastasis Reviews.

[37]  P. M. Das,et al.  Downregulation of miR-342 is associated with tamoxifen resistant breast tumors , 2010, Molecular Cancer.

[38]  Per Karlsson,et al.  Clinical Implications of Gene Dosage and Gene Expression Patterns in Diploid Breast Carcinoma , 2010, Clinical Cancer Research.

[39]  E. Espinosa,et al.  Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. , 2010, BioTechniques.

[40]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[41]  Jeffrey D Orth,et al.  What is flux balance analysis? , 2010, Nature Biotechnology.

[42]  Pilar Zamora,et al.  An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer , 2010, BMC Cancer.

[43]  David Edwards,et al.  High-dimensional Graphical Model Search with gRapHD R Package , 2009, 0909.1234.

[44]  Lukas N. Mueller,et al.  Full Dynamic Range Proteome Analysis of S. cerevisiae by Targeted Proteomics , 2009, Cell.

[45]  Desmond S. Lun,et al.  Interpreting Expression Data with Metabolic Flux Models: Predicting Mycobacterium tuberculosis Mycolic Acid Production , 2009, PLoS Comput. Biol..

[46]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[48]  Christophe Lemetre,et al.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.

[49]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[50]  Tyler E. Miller,et al.  MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.

[51]  Henry H. N. Lam,et al.  PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows , 2008, EMBO reports.

[52]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[53]  R. Deberardinis,et al.  Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis , 2007, Proceedings of the National Academy of Sciences.

[54]  H. Nevanlinna,et al.  Mast cells and eosinophils in invasive breast carcinoma , 2007, BMC Cancer.

[55]  György Marko-Varga,et al.  Personalized medicine and proteomics: lessons from non-small cell lung cancer. , 2007, Journal of proteome research.

[56]  G. D’Arrigo,et al.  Mast cells in invasive ductal breast cancer: different behavior in high and minimum hormone-receptive cancers. , 2007, Anticancer research.

[57]  Yuval Kluger,et al.  High HSP90 expression is associated with decreased survival in breast cancer. , 2007, Cancer research.

[58]  S. Leung,et al.  Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases , 2007, Breast Cancer Research and Treatment.

[59]  S. Somiari,et al.  Proteomics in human cancer research , 2007, Proteomics. Clinical applications.

[60]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[61]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[62]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[63]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[64]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[65]  D. Huntsman,et al.  The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis , 2004, Modern Pathology.

[66]  Richard Simon,et al.  A random variance model for detection of differential gene expression in small microarray experiments , 2003, Bioinform..

[67]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[68]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[69]  S. Hanash.  Disease proteomics : Proteomics , 2003 .

[70]  S. Hanash,et al.  Disease proteomics , 2003, Nature.

[71]  Peter H Watson,et al.  Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  M. Radmacher,et al.  Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.

[73]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[74]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[76]  Luis Moroder,et al.  Structure of TPR Domain–Peptide Complexes Critical Elements in the Assembly of the Hsp70–Hsp90 Multichaperone Machine , 2000, Cell.

[77]  G. Schwarz.  Estimating the Dimension of a Model , 1978 .